Novo Nordisk sets 2026 AGM and board elections
Novo Nordisk A/S has called its Annual General Meeting for 26 March 2026 at 14:00 (CET).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Novo Nordisk A/S has called its Annual General Meeting for 26 March 2026 at 14:00 (CET). The meeting will be held as a combined physical and virtual event, allowing shareholders to attend at Bella Center in Copenhagen or participate online by computer or mobile device.
Shareholders are encouraged to submit proxies or votes by correspondence in advance, with practical details provided in the accompanying meeting notice and via a live webcast. All shareholder-elected Board members are up for election, and the Board proposes re-electing Lars Rebien Sørensen as Chair, Cees de Jong as Vice Chair, and several other members, while nominating Helena Saxon, Jan van de Winkel and Ramona Sequeira as new Board members.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is Novo Nordisk (NVO) holding its 2026 Annual General Meeting?
Which Board positions are up for election at Novo Nordisk’s 2026 AGM?
Who are the new Board member nominees at Novo Nordisk (NVO) in 2026?
Can investors follow Novo Nordisk’s 2026 Annual General Meeting by webcast?
Where will Novo Nordisk’s 2026 Annual General Meeting be held physically?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 20, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Notice for the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 20 February 2026 – The Annual General Meeting will be held on:
Thursday 26 March 2026 at 14:00 (CET)
The Annual General Meeting will be held as a combined physical and virtual meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, entrance 6, 2300 Copenhagen S, Denmark, or virtually by PC or smartphone/tablet. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting. Further details on registration and participation are included in the enclosed meeting notice.
Novo Nordisk offers shareholders and others to follow the Annual General Meeting via live webcast on Novo Nordisk’s website. Please refer to the enclosed meeting notice for further information on the webcast.
BOARD OF DIRECTORS
All shareholder-elected Board members are up for election.
The Board of Directors proposes re-election of Lars Rebien Sørensen as Chair of the Board and re-election of Cees de Jong as Vice Chair. Moreover, the Board proposes re-election of Britt Meelby Jensen, Stephan Engels and Kasim Kutay. The Board proposes Helena Saxon, Jan van de Winkel and Ramona Sequeira as new members of the Board of Directors.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Novo Nordisk Media: | |
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| globalmedia@novonordisk.com | lzsk@novonordisk.com |
| Novo Nordisk Investors: | |
| Michael Novod | Jacob Martin Wiborg Rode |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| Sina Meyer | Max Ung |
| +45 3079 6656 | +45 3077 6414 |
| azey@novonordisk.com | mxun@novonordisk.com |
| Christoffer Sho Togo Tullin | Alex Bruce |
| +45 3079 1471 | +45 3444 2613 |
| cftu@novonordisk.com | axeu@novonordisk.com |
| Frederik Taylor Pitter | |
| +1 609 613 0568 | |
| fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 12/ 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 20, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |